253 related articles for article (PubMed ID: 25779351)
1. Measurement of low amounts of amorphous content in hydrophobic active pharmaceutical ingredients with dynamic organic vapor sorption.
Müller T; Schiewe J; Smal R; Weiler C; Wolkenhauer M; Steckel H
Eur J Pharm Biopharm; 2015 May; 92():102-11. PubMed ID: 25779351
[TBL] [Abstract][Full Text] [Related]
2. Influence of small amorphous amounts in hydrophilic and hydrophobic APIs on storage stability of dry powder inhalation products.
Müller T; Krehl R; Schiewe J; Weiler C; Steckel H
Eur J Pharm Biopharm; 2015 May; 92():130-8. PubMed ID: 25769680
[TBL] [Abstract][Full Text] [Related]
3. Applicability of the one-step DVS method for the determination of amorphous amounts for further different hydrophilic and hydrophobic drugs.
Müller T; Scherließ R; Schiewe J; Smal R; Weiler C; Steckel H
Eur J Pharm Biopharm; 2015 Aug; 94():333-41. PubMed ID: 26079523
[TBL] [Abstract][Full Text] [Related]
4. Following mechanical activation of salbutamol sulphate during ball-milling with isothermal calorimetry.
Gaisford S; Dennison M; Tawfik M; Jones MD
Int J Pharm; 2010 Jun; 393(1-2):74-8. PubMed ID: 20385222
[TBL] [Abstract][Full Text] [Related]
5. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
6. A novel method for the production of crystalline micronised particles.
Muhammad SA; Langrish T; Tang P; Adi H; Chan HK; Kazarian SG; Dehghani F
Int J Pharm; 2010 Mar; 388(1-2):114-22. PubMed ID: 20043982
[TBL] [Abstract][Full Text] [Related]
7. Process-induced crystallinity changes in albuterol sulfate and its effect on powder physical stability.
Ward GH; Schultz RK
Pharm Res; 1995 May; 12(5):773-9. PubMed ID: 7479567
[TBL] [Abstract][Full Text] [Related]
8. Reducing mechanical activation-induced amorphisation of salbutamol sulphate by co-processing with selected carboxylic acids.
Curtin V; Amharar Y; Gallagher KH; Corcoran S; Tajber L; Corrigan OI; Healy AM
Int J Pharm; 2013 Nov; 456(2):508-16. PubMed ID: 23994365
[TBL] [Abstract][Full Text] [Related]
9. The use of organic vapor sorption to determine low levels of amorphous content in processed pharmaceutical powders.
Young PM; Chiou H; Tee T; Traini D; Chan HK; Thielmann F; Burnett D
Drug Dev Ind Pharm; 2007 Jan; 33(1):91-7. PubMed ID: 17192255
[TBL] [Abstract][Full Text] [Related]
10. Determination of low levels of amorphous content in inhalation grade lactose by moisture sorption isotherms.
Vollenbroek J; Hebbink GA; Ziffels S; Steckel H
Int J Pharm; 2010 Aug; 395(1-2):62-70. PubMed ID: 20493937
[TBL] [Abstract][Full Text] [Related]
11. Measurement of the Raman spectra and hygroscopicity of four pharmaceutical aerosols as they travel from pressurised metered dose inhalers (pMDI) to a model lung.
Davidson N; Tong HJ; Kalberer M; Seville PC; Ward AD; Kuimova MK; Pope FD
Int J Pharm; 2017 Mar; 520(1-2):59-69. PubMed ID: 28159683
[TBL] [Abstract][Full Text] [Related]
12. Determining the critical relative humidity for moisture-induced phase transitions.
Burnett DJ; Thielmann F; Booth J
Int J Pharm; 2004 Dec; 287(1-2):123-33. PubMed ID: 15541919
[TBL] [Abstract][Full Text] [Related]
13. Characterization and quantification of amorphous material in milled and spray-dried salbutamol sulfate: a comparison of thermal, spectroscopic, and water vapor sorption approaches.
Grisedale LC; Jamieson MJ; Belton P; Barker SA; Craig DQM
J Pharm Sci; 2011 Aug; 100(8):3114-3129. PubMed ID: 21456029
[TBL] [Abstract][Full Text] [Related]
14. Conditioning following powder micronization: influence on particle growth of salbutamol sulfate.
Brodka-Pfeiffer K; Häusler H; Grass P; Langguth P
Drug Dev Ind Pharm; 2003 Nov; 29(10):1077-84. PubMed ID: 14677768
[TBL] [Abstract][Full Text] [Related]
15. Hollow crystalline straws of diclofenac for high-dose and carrier-free dry powder inhaler formulations.
Yazdi AK; Smyth HD
Int J Pharm; 2016 Apr; 502(1-2):170-80. PubMed ID: 26911418
[TBL] [Abstract][Full Text] [Related]
16. How does secondary processing affect the physicochemical properties of inhalable salbutamol sulphate particles? A temporal investigation.
Pinto JT; Radivojev S; Zellnitz S; Roblegg E; Paudel A
Int J Pharm; 2017 Aug; 528(1-2):416-428. PubMed ID: 28619456
[TBL] [Abstract][Full Text] [Related]
17. Quantifying the degree of disorder in micronized salbutamol sulfate using moisture sorption analysis.
Gorny M; Jakobs M; Mykhaylova V; Urbanetz NA
Drug Dev Ind Pharm; 2007 Mar; 33(3):235-43. PubMed ID: 17454056
[TBL] [Abstract][Full Text] [Related]
18. Quantification of low levels of amorphous content in crystalline celecoxib using dynamic vapor sorption (DVS).
Sheokand S; Modi SR; Bansal AK
Eur J Pharm Biopharm; 2016 May; 102():77-86. PubMed ID: 26948976
[TBL] [Abstract][Full Text] [Related]
19. Mutual Impact of Phase Separation/Crystallization and Water Sorption in Amorphous Solid Dispersions.
Luebbert C; Wessner M; Sadowski G
Mol Pharm; 2018 Feb; 15(2):669-678. PubMed ID: 29309155
[TBL] [Abstract][Full Text] [Related]
20. An example of how to handle amorphous fractions in API during early pharmaceutical development: SAR114137--a successful approach.
Petzoldt C; Bley O; Byard SJ; Andert D; Baumgartner B; Nagel N; Tappertzhofen C; Feth MP
Eur J Pharm Biopharm; 2014 Apr; 86(3):337-50. PubMed ID: 24075979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
